-
Tytuł:
-
High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity.
-
Autorzy:
-
Vazquez-Lombardi R; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland; Engimmune Therapeutics AG, Hegenheimermattweg 167A, 4123 Allschwil, Switzerland. Electronic address: .
Jung JS; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland.
Schlatter FS; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland.
Mei A; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland.
Mantuano NR; Department of Biomedicine, Universitätsspital Basel, Basel, Switzerland.
Bieberich F; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland.
Hong KL; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland.
Kucharczyk J; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland.
Kapetanovic E; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland.
Aznauryan E; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland.
Weber CR; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland.
Zippelius A; Department of Biomedicine, Universitätsspital Basel, Basel, Switzerland.
Läubli H; Department of Biomedicine, Universitätsspital Basel, Basel, Switzerland.
Reddy ST; Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, 4058 Basel, Switzerland. Electronic address: .
-
Źródło:
-
Immunity [Immunity] 2022 Oct 11; Vol. 55 (10), pp. 1953-1966.e10. Date of Electronic Publication: 2022 Sep 28.
-
Typ publikacji:
-
Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Cambridge, MA : Cell Press
Original Publication: Cambridge, Mass. : Cell Press, c1994-
-
MeSH Terms:
-
Immunotherapy, Adoptive*
Receptors, Antigen, T-Cell*
Antigens, Neoplasm ; Humans ; Immunotherapy ; Peptides
-
Contributed Indexing:
-
Keywords: T cell receptor; TCR; deep sequencing; immunotherapy; protein engineering
-
Substance Nomenclature:
-
0 (Antigens, Neoplasm)
0 (Peptides)
0 (Receptors, Antigen, T-Cell)
-
Entry Date(s):
-
Date Created: 20220929 Date Completed: 20221014 Latest Revision: 20221018
-
Update Code:
-
20240105
-
DOI:
-
10.1016/j.immuni.2022.09.004
-
PMID:
-
36174557
-
A major challenge in adoptive T cell immunotherapy is the discovery of natural T cell receptors (TCRs) with high activity and specificity to tumor antigens. Engineering synthetic TCRs for increased tumor antigen recognition is complicated by the risk of introducing cross-reactivity and by the poor correlation that can exist between binding affinity and activity of TCRs in response to antigen (peptide-MHC). Here, we developed TCR-Engine, a method combining genome editing, computational design, and deep sequencing to engineer the functional activity and specificity of TCRs on the surface of a human T cell line at high throughput. We applied TCR-Engine to successfully engineer synthetic TCRs for increased potency and specificity to a clinically relevant tumor-associated antigen (MAGE-A3) and validated their translational potential through multiple in vitro and in vivo assessments of safety and efficacy. Thus, TCR-Engine represents a valuable technology for engineering of safe and potent synthetic TCRs for immunotherapy applications.
Competing Interests: Declaration of interests ETH Zurich has filed for patent protection on the technology and sequences described herein, and R.V.-L., J.S.J., and S.T.R. are named as co-inventors on this patent (WO2021074249A1). R.V.-L and S.T.R. are co-founders and hold shares of Engimmune Therapeutics AG. S.T.R. may hold shares of Alloy Therapeutics. S.T.R. is on the scientific advisory board of Engimmune Therapeutics and Alloy Therapeutics.
(Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)